Home > Oral naltrexone maintenance treatment for opioid dependence.

Minozzi, Silvia and Amato, Laura and Vecchi, Simona and Davoli, Marina and Kirchmayer, Ursula and Verster, Annette (2011) Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database of Systematic Reviews, (4), Art. No.: CD001333. DOI: 10.1002/14651858.CD001333.pub4.

External website: https://www.cochranelibrary.com/cdsr/doi/10.1002/1...

Opioid dependence is considered to be a lifelong, chronic relapsing disorder. Substantial therapeutic efforts are needed to keep people drug free. Methadone treatment plays a vital role in detoxification or maintenance programs but some individuals who are on methadone continue to use illicit drugs, commit crime and engage in behaviours that promote the spread of communicable diseases. Naltrexone is a long acting opioid antagonist that does not produce euphoria and is not addicting. It is used in accidental heroin overdose and for the treatment of people who have opioid dependence. Naltrexone is particularly suitable to prevent a relapse to opioid use after heroin detoxification for those for whom failure to comply with treatment has major consequences, for example health professionals, business executives and individuals under legal supervision. Medication compliance and retention rates with naltrexone treatment are however low.

In this review of the medical literature oral naltrexone, with or without psychotherapy, was no better than placebo or no pharmacological treatments with regard to retention in treatment, use of the primary substance of abuse or side effects. The only outcome that was clearly in favour of naltrexone was a reduction of re incarcerations by about a half but these results were from only two studies. In single studies naltrexone was not superior to benzodiazepines or buprenorphine for retention, abstinence or side effects. The review authors identified a total of 13 randomised controlled studies that involved 1158 opioid addicts treated as outpatients following detoxification. Less than a third of participants were retained in treatment over the duration of the included studies. The mean duration was six months (range one to 10 months). None of included studies considered deaths from fatal overdoses in people treated with naltrexone.

Item Type
Publication Type
International, Review, Article
Drug Type
Intervention Type
Drug therapy, Treatment method
April 2011
Identification #
Art. No.: CD001333. DOI: 10.1002/14651858.CD001333.pub4
John Wiley & Sons, Ltd
Accession Number
HRB (Electronic Only)

Click here to request a copy of this literature

Repository Staff Only: item control page